Journal of Antimicrobial Chemotherapy, Vol 39, 371-381, Copyright © 1997 by The British Society for Antimicrobial Chemotherapy
TM Korman, JD Turnidge and ML Grayson
We retrospectively studied adverse cutaneous reactions associated with
intravenous vancomycin therapy over a 14-month period when two different
brands of vancomycin were used. Of 224 adults, 12 (5.4%) had
infusion-related reactions; ten of 174 patients who received more than one
day of vancomycin (5.7%) had delayed cutaneous reactions. Age less than 40
years was a risk factor for both infusion-related and delayed reactions by
both univariate and multivariate analysis. Duration of therapy greater than
7 days was a risk factor for delayed reactions. There was a significant
increase in adverse cutaneous reactions associated with the use of a
particular batch of vancomycin, although analytical testing of this batch
failed to identify any difference from other batches associated with
routine rates of adverse reactions. Awareness of vancomycin-associated
infusion-related and delayed cutaneous reactions is necessary, and the risk
factors associated with these reactions may have important clinical
implications.
JOURNAL ARTICLE
Risk factors for adverse cutaneous reactions associated with intravenous vancomycin
Department of Infectious Diseases and Microbiology, Monash Medical Centre, Clayton, VIC, Australia.
![]()
CiteULike
Connotea
Del.icio.us What's this?